吉林省医药制造业创新效率问题研究
发布时间：2018-12-07 20:49
【摘要】：医药制造业是国民经济中一个具有特殊地位的产业,关系到国民之健康、社会之稳定以及经济之发展,是世界公认的知识、技术、资本密集的高技术产业。我国医药制造业起步相对较晚但发展迅速,年均增速一直保持在两位数以上,在制造业各大类行业中始终位居前列。2016年2月14日,李克强总理在国务院常务会议上提出医药产业关系民众健康,市场需求巨大,应积极扶持中医药发展,全面推动医药产业创新升级。这说明,作为医药产业核心的医药制造业已被推到了我国创新改革的风口浪尖。吉林省地处我国东北部地区,医药制造业独具特色,中成药生产企业规模占比近70%。本文通过数据的对比与研究发现,虽然吉林省医药制造业已具备一定规模,但知识化、技术化水平较低,发展模式仍属于资源依赖性。本文通过借鉴国内外学者关于创新及创新效率理论与方法的最新研究成果,对吉林省医药制造业创新效率进行测算,测算结果表明:吉林省医药制造业近几年创新效率相比全国其他地区有上升趋势,排名相对靠前,但主要是由于创新投入尚处在规模报酬递增阶段,是创新投入增加对创新效率拉动的结果;虽然纯技术效率也有所提升,但跟医药制造业发达地区(如山东省、江苏省等)相比仍然相距甚远。更近一步,本文选择具有代表性的山东省和四川省进行案例分析,并对吉林省医药制造业各影响因素进行实证检验,最终得出结论:倡导制药企业创新文化,增加制药企业创新投入强度,是提升吉林省医药制造业创新效率的根本动力;只有充分激发制药企业的创造活力,才能够引领吉林省医药制造业早日走上创新升级之路。在此基础上,本文结合吉林省医药制造业发展特征,有针对性地提出对策和建议。
[Abstract]:Pharmaceutical manufacturing industry is an industry with special status in the national economy, which is related to the health of the people, the stability of society and the development of economy. It is recognized as a high-tech industry with knowledge, technology and capital density in the world. China's pharmaceutical manufacturing industry started relatively late but developed rapidly, with an average annual growth rate of more than double digits, and has always been in the forefront of all kinds of manufacturing industries. On February 14, 2016, Premier Li Keqiang put forward at the executive meeting of the State Council that the pharmaceutical industry has a healthy relationship with the people, and the market demand is enormous, so we should actively support the development of traditional Chinese medicine and promote the innovation and upgrading of the pharmaceutical industry in an all-round way. This shows that the pharmaceutical manufacturing industry as the core of the pharmaceutical industry has been pushed to the forefront of innovation and reform in China. Jilin Province is located in the northeast of China, the pharmaceutical manufacturing industry has its own characteristics, the scale of the Chinese patent medicine production enterprises accounts for nearly 70%. Through the comparison and study of the data, it is found that although the pharmaceutical manufacturing industry in Jilin Province has a certain scale, but the level of knowledge and technology is low, the development mode is still resource-dependent. Based on the latest research results of innovation and innovation efficiency theories and methods at home and abroad, this paper measures the innovation efficiency of pharmaceutical manufacturing industry in Jilin Province. The results show that the innovation efficiency of the pharmaceutical manufacturing industry in Jilin Province has an upward trend compared with other regions in the country in recent years, and the ranking is relatively high, but mainly because the innovation investment is still in the stage of increasing returns on a scale. It is the result of the increase of innovation input to the efficiency of innovation. Although pure technology efficiency has also improved, it is still far from the pharmaceutical manufacturing developed regions (such as Shandong, Jiangsu Province, etc.). Further, this paper chooses Shandong Province and Sichuan Province, which are representative, to carry on the case analysis, and carries on the empirical examination to the Jilin Province medicine manufacturing industry each influence factor, finally draws the conclusion: advocates the pharmaceutical enterprise innovation culture, Increasing the innovation input intensity of pharmaceutical enterprises is the fundamental motive force to improve the innovation efficiency of pharmaceutical manufacturing industry in Jilin Province. Only by fully stimulating the creative vitality of pharmaceutical enterprises can we lead the pharmaceutical manufacturing industry in Jilin Province to embark on the road of innovation and upgrading as soon as possible. On this basis, this paper puts forward countermeasures and suggestions according to the development characteristics of pharmaceutical manufacturing industry in Jilin Province.
【学位授予单位】：吉林大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F426.72;F273.1
本文编号：2367847
[Abstract]:Pharmaceutical manufacturing industry is an industry with special status in the national economy, which is related to the health of the people, the stability of society and the development of economy. It is recognized as a high-tech industry with knowledge, technology and capital density in the world. China's pharmaceutical manufacturing industry started relatively late but developed rapidly, with an average annual growth rate of more than double digits, and has always been in the forefront of all kinds of manufacturing industries. On February 14, 2016, Premier Li Keqiang put forward at the executive meeting of the State Council that the pharmaceutical industry has a healthy relationship with the people, and the market demand is enormous, so we should actively support the development of traditional Chinese medicine and promote the innovation and upgrading of the pharmaceutical industry in an all-round way. This shows that the pharmaceutical manufacturing industry as the core of the pharmaceutical industry has been pushed to the forefront of innovation and reform in China. Jilin Province is located in the northeast of China, the pharmaceutical manufacturing industry has its own characteristics, the scale of the Chinese patent medicine production enterprises accounts for nearly 70%. Through the comparison and study of the data, it is found that although the pharmaceutical manufacturing industry in Jilin Province has a certain scale, but the level of knowledge and technology is low, the development mode is still resource-dependent. Based on the latest research results of innovation and innovation efficiency theories and methods at home and abroad, this paper measures the innovation efficiency of pharmaceutical manufacturing industry in Jilin Province. The results show that the innovation efficiency of the pharmaceutical manufacturing industry in Jilin Province has an upward trend compared with other regions in the country in recent years, and the ranking is relatively high, but mainly because the innovation investment is still in the stage of increasing returns on a scale. It is the result of the increase of innovation input to the efficiency of innovation. Although pure technology efficiency has also improved, it is still far from the pharmaceutical manufacturing developed regions (such as Shandong, Jiangsu Province, etc.). Further, this paper chooses Shandong Province and Sichuan Province, which are representative, to carry on the case analysis, and carries on the empirical examination to the Jilin Province medicine manufacturing industry each influence factor, finally draws the conclusion: advocates the pharmaceutical enterprise innovation culture, Increasing the innovation input intensity of pharmaceutical enterprises is the fundamental motive force to improve the innovation efficiency of pharmaceutical manufacturing industry in Jilin Province. Only by fully stimulating the creative vitality of pharmaceutical enterprises can we lead the pharmaceutical manufacturing industry in Jilin Province to embark on the road of innovation and upgrading as soon as possible. On this basis, this paper puts forward countermeasures and suggestions according to the development characteristics of pharmaceutical manufacturing industry in Jilin Province.
【学位授予单位】：吉林大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F426.72;F273.1
【参考文献】
相关期刊论文 前10条
1 苗婧;杨海亮;;京津冀协同发展与河北产业创新升级研究[J];经济研究参考;2016年53期
2 徐伟;仲忆雯;郝梅;;基于因子分析和熵权法的我国医药产业创新政策实施效果评价[J];上海医药;2016年15期
3 罗文华;孙利华;周静;;中国医药产业结构高级化评价[J];中国新药杂志;2016年14期
4 李洁;周秋芳;;江苏医药产业集群知识溢出效应实证分析[J];南京中医药大学学报(社会科学版);2016年02期
5 苗葳;;实施创新驱动战略 推动通化医药健康产业发展[J];延边党校学报;2016年02期
6 赵冠宇;;关于我国医药产业集群投资风险的分析[J];时代金融;2016年05期
7 王红倩;张峥;;基于SD的医药产业技术创新系统研究[J];上海理工大学学报;2016年01期
8 武兴连;席晓宇;姚文兵;;基于齿轮模型的医药产业与区域经济耦合协调度研究[J];中国新药杂志;2016年02期
9 严朕;修国义;;黑龙江省医药产业集群创新能力评价研究[J];科技与管理;2016年01期
10 蔡仲曦;干荣富;;从医药产业链维度寻找医药工业发展之契机[J];中国医药工业杂志;2016年01期
，本文编号：2367847
本文链接：https://www.wllwen.com/jingjilunwen/xmjj/2367847.html
